Advertisement

Picture EBD Group BioPharm America 2020 Digital Event BEU2020 650x81
Financing › Details

Temedica–SEVERAL: investment, 202001 financing round Series B €17m led by MIG Funds + Santo VC + Salvia

 

Period Period 2020-01-14
Organisations Money taker Temedica GmbH
  Money source SEVERAL
Products Product digital health
  Product 2 venture capital
Person Person Motschmann, Michael (MIG Funds 200604)
     

Temedica GmbH. (1/14/20). "Press Release: Temedica Raises $19 Million Series B Funding". Munich.

In order to further strengthen its position as an innovation driver in the fast-growing digital health market, Temedica has closed a Series B financing round of $19 million. The round was led by MIG Funds, Santo Venture Capital and Salvia, along with existing investors such as Bernd Wendeln and G+J Digital Ventures.


Digital health company Temedica has successfully completed a $19 million Series B financing round led by the MIG funds, Santo Venture Capital and Salvia.

Temedica develops digital therapy companions as smartphone apps that aim to support patients’ healing process and to ensure sustainable medical care. A long-term and lasting improvement in health often requires behavioral changes and active monitoring of the therapy. Temedica develops digital solutions for a wide range of indications, enabling patients to proactively support their healing process and prevent the development of diseases. Several of Temedica's products are developed in cooperation with partners, with a strong focus on medical evidence.

The young company has two outstanding features: On the one hand, digital medical products can be brought to market quickly and efficiently due to the platform's broad positioning and use of synergies. On the other hand, Temedica uses findings from Real-World Data to generate previously unknown insights regarding the relationships between disease occurrences and symptoms.

With this investment, Temedica intends to further develop its app development platform and cover additional indications - especially in the area of chronic diseases.

Gloria Seibert, Founder & CEO of Temedica says:
With this investment we are able to continue our growth and develop digital patient companions for new indications. I am pleased that we have been able to improve the health of many people to date and deliver great value to patients. With MIG, Santo and Salvia we gain valuable expertise in the healthcare market and strong partners for the upcoming expansion of the organization.

Michael Motschmann, General Partner of MIG AG, says:
With Temedica's intelligent digital approach we complement our traditionally strong foothold in the health sector. We want to participate in the great potential of the future market for digital health services.


ABOUT TEMEDICA

Launched in 2016, Temedica develops digital companions for patients to support their healing process and improve their medical care. To date, the company has developed products such as pelvina (for a strong pelvic floor), Mineo (for a strong back) and Waya (for healthy nutrition and exercise). Further developments are planned.


ABOUT MIG

MIG Verwaltungs AG (MIG AG) is one of the leading German VC investors. Through the MIG funds, young companies are provided with the financial means to establish and finance growth in the hightech and life science sectors.

For further information: www.mig.ag | www.mig-fonds.de


ABOUT SANTO

Santo Venture Capital GmbH is the venture arm of ATHOS KG, the family office of the Strüngmann families.


CONTACT

Gloria Seibert, Gründerin & CEO
gloria.seibert@temedica.com

   
Record changed: 2020-02-02

Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for Temedica GmbH


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Kentro Design Corporate and Web Design Berlin 650x65px




» top